[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576472":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":32,"locations":41,"responsibleParty":97,"collaborators":100,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":105,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":10,"studyType":117,"phases":10,"briefSummary":118,"conditions":119,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Statin continued",null,"Patients in which the statin was continued after the index event",[13],"Drug: Statin",{"label":15,"type":10,"description":16,"interventionNames":10},"Statin discontinued","Patients in which the statin was discontinued after the index event",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Statin","Statin use",[9],[24],"atorvastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin",[26,30],{"name":27,"affiliation":28,"role":29},"Renske van den Berg-Vos, Prof. dr.","Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":28,"role":29},"Nathalie van der Velde, Prof. dr.",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Susanna R Prins, MSc","CONTACT","0031 20 566 9111","s.r.prins@amsterdamumc.nl",{"name":39,"role":35,"phone":36,"phoneExt":10,"email":40},"Birgit A Damoiseaux-Volman, PhD","b.a.damoiseaux@amsterdamumc.nl",[42,59,71,84],{"facility":43,"status":44,"city":45,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Flevoziekenhuis","RECRUITING","Almere Stad","Netherlands","NL",{"type":49,"coordinates":50},"Point",[51,52],5.21413,52.37025,{"lat":52,"lon":51},[55],{"name":56,"role":35,"phone":57,"phoneExt":10,"email":58},"Elizabeth Osei, MD, PHD","0031368688720","losei@flevoziekenhuis.nl",{"facility":60,"status":44,"city":61,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Amsterdam UMC, location AMC","Amsterdam",{"type":49,"coordinates":63},[64,65],4.88969,52.37403,{"lat":65,"lon":64},[68],{"name":69,"role":35,"phone":70,"phoneExt":10,"email":37},"Susanna Prins, MD","0031205669111",{"facility":72,"status":44,"city":73,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Catharina Ziekenhuis","Eindhoven",{"type":49,"coordinates":75},[76,77],5.47778,51.44083,{"lat":77,"lon":76},[80],{"name":81,"role":35,"phone":82,"phoneExt":10,"email":83},"Rob Gons, MD, PHD","031402399426","rob.gons@catharinaziekenhuis.nl",{"facility":85,"status":44,"city":86,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Isala Klinieken","Zwolle",{"type":49,"coordinates":88},[89,90],6.09444,52.5125,{"lat":90,"lon":89},[93],{"name":94,"role":35,"phone":95,"phoneExt":10,"email":96},"Wilmar Jolink, MD, PHD","0031886242461","w.m.t.jolink@isala.nl",{"type":29,"investigatorFullName":98,"investigatorTitle":99,"investigatorAffiliation":60,"oldNameTitle":10,"oldOrganization":10},"Prof. dr. Nathalie van der Velde","Professor dr. Nathalie van der Velde, Full Professor Geriatric medicine (internal medicine)",[101],{"name":102,"class":6},"VU University of Amsterdam","100576472","statins-in-frail-older-patients-with-ischemic-stroke-or-transient-ischemic-attack---the-prospective-cohort-study-100576472",false,"NCT06785740","Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","SAFEST-coh","Inclusion Criteria:\n\n* age = 70 years or older at the time of ischemic stroke or TIA;\n* inclusion within 6 weeks after diagnosis of ischemic stroke or TIA;\n* already using statin therapy at the time of the index event;\n* frailty as defined by a pre-event score of 4-7 and\u002For post-event score of 6-7 on the validated Clinical Frailty Scale.\n\nExclusion Criteria:\n\n* Previous serious adverse drug reactions (defined as an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisa-tion, results in persistent or significant disability or incapacity, or is a birth defect32) to statins or other contraindications to statin use.\n* Very severe frailty or very limited life expectancy (\\\u003C 6 months) as defined by a score \\>= 8 points on the validated Clinical Frailty Scale.\n* Inability to communicate in Dutch.\n* Inability to respond to questions, either independently or with the assistance of a proxy.\n* Inability or unwillingness to provide written informed consent, either independently or with the assistance of a proxy.","ALL","70 Years","120 Years",{"count":115,"type":116},300,"ESTIMATED","OBSERVATIONAL","Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST-cohort, the investigators will assess the impact of continuing versus discontinuing a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and MACE free survival during a two-year follow-up period.",[120,121],"Ischemic Stroke","TIA","2025-01-19",{"date":124,"type":125},"2025-01-21","ACTUAL",{"date":127,"type":125},"2024-11-01",{"date":129,"type":116},"2029-09",{"name":5,"class":6},4]